Amycretin

zenagamtide, GLP-1/amylinMetabolic/Weight

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss

MechanismSingle molecule with both GLP-1 and amylin receptor agonism, in subcutaneous and oral formulations.

EffectsIn a Phase Ib/IIa trial, 22% average weight reduction at the 20 mg weekly subcutaneous dose over 36 weeks against roughly 2% weight gain on placebo — and weight loss had not plateaued at week 36.

DosingNo human dose established.

Bottom lineThe most striking Phase 2 weight-loss figure in the class so far, and still an investigational drug.

Not a dose · what the literature contains instead

Phase Ib/IIa used up to 20 mg once weekly subcutaneously for 36 weeks; a Phase 3 programme was planned to begin in early 2026. Not available outside a trial.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Investigational. GI effects consistent with the GLP-1 class. Long-term safety is not established, and the Phase 3 programme has not read out.

Expected to follow the GLP-1 class: caution with insulin and sulfonylureas, and delayed gastric emptying affecting oral drug absorption. Not formally studied.

CV 2 of 5 — Weight and HbA1c reductions are risk-factor improvements, not outcomes. No cardiovascular outcomes data exists.